China
Africa
Explore chapters and articles related to this topic
Laboratory and Clinical Follow-Up
Published in Ayse Serap Karadag, Berna Aksoy, Lawrence Charles Parish, Retinoids in Dermatology, 2019
Nadide Burcu Öztürk, Berna Aksoy
Retinoids are metabolites and synthetic analogs of vitamin A (retinol) that are not only commonly used in dermatologic practice, but are also irreplaceable in the treatment of many diseases, including acne and psoriasis. The primary drugs in this group include isotretinoin, acitretin, bexarotene, and alitretinoin. Isotretinoin, acitretin, and bexarotene have been approved by the United States Food and Drug Administration (FDA) for the treatment of acne, psoriasis, and cutaneous T-cell lymphoma, respectively, but they have been used in the treatment of many other diseases with success. Alitretinoin is used for chronic hand dermatitis.
Alitretinoin
Published in Sarah H. Wakelin, Howard I. Maibach, Clive B. Archer, Handbook of Systemic Drug Treatment in Dermatology, 2015
A large randomized placebo controlled study has demonstrated the efficacy of alitretinoin in adult patients with severe chronic hand eczema (referred to as the ‘BACH’ – Benefit of Alitretinoin in Chronic Hand eczema study). This reported that almost half of all patients receiving the higher (30 mg daily) dose achieved a rating of ‘clear’ or ‘almost clear’ at the 24 week endpoint. The lower dose (10 mg daily) was less effective but superior to placebo. Both hyperkeratotic disease and pompholyx/fingertip variants of hand eczema were reported to respond.
Hand Dermatitis
Published in Donald Rudikoff, Steven R. Cohen, Noah Scheinfeld, Atopic Dermatitis and Eczematous Disorders, 2014
Nina C. Botto, Erin M. Warshaw
More recently, the BACH (Benefit of Alitretinoin in Chronic Hand dermatitis) study of 1032 patients examined the effect on chronic severe hand eczema of 10 or 30 mg oral alitretinoin once daily for up to 24 weeks (Ruzicka et al. 2008). Up to 48% of patients treated with alitretinoin achieved clear or almost clear hands. In a follow-up study, patients originally treated with alitretinoin in the BACH study were randomized to receive either their previous alitretinoin dose or placebo for 12 or 24 weeks (Coenraads et al. 2008). Retreatment with alitretinoin was effective in most cases and was well tolerated; the best response rates were seen with the 30 mg dosage. In a commentary on the BACH study, Ingram et al. (2009) suggested that the authors’ claim of remission in a high proportion of patients was rather inflated insofar as ‘only slightly less than half of participants responded to the 30 mg dose; only 28% responded to the 10 mg dose; and the corresponding percentage responses for patient-reported outcomes were even less (40% and 24% respectively).’
Alitretinoin for the treatment of severe chronic eczema of the hands
Published in Expert Opinion on Pharmacotherapy, 2022
Maddalena Napolitano, Luca Potestio, Mario De Lucia, Mariateresa Nocerino, Gabriella Fabbrocini, Cataldo Patruno
A search of the PubMed, Embase, and Cochrane Skin databases and that of clinicaltrials.gov was performed [until July 3,2021]. The search terms were ‘alitretinoin’ and ‘chronic hand eczema.’ Only English-language publications were selected. Clinical trials, case series, and case reports on alitretinoin and CHE were included. Then, a revision of the abstracts and texts of the articles was made independently by each author. As a result, a total of 38 publications and clinical trials were selected for the evaluation in this review Figure 1.